​

Atara Biotherapeutics (ATRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ATRA Stock Forecast

Atara Biotherapeutics (ATRA) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $9.50, with a high of $13.00 and a low of $6.00. This represents a 1.71% increase from the last price of $9.34.

- $3 $6 $9 $12 $15 High: $13 Avg: $9.5 Low: $6 Last Closed Price: $9.34

ATRA Stock Rating

Atara Biotherapeutics stock's rating consensus is Hold, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (30.77%), 7 Hold (53.85%), 2 Sell (15.38%), and 0 Strong Sell (0.00%).

Hold
Total 13 0 2 7 4 Strong Sell Sell Hold Buy Strong Buy

ATRA Price Target Upside V Benchmarks

TypeNameUpside
StockAtara Biotherapeutics1.71%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$13.00$13.00$14.67
Last Closing Price$9.34$9.34$9.34
Upside/Downside39.19%39.19%57.07%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 26-111-3
Apr, 26-111-3
Mar, 26-121-4
Feb, 26-221-5
Jan, 26-41--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 08, 2026Canaccord Genuity$13.00$9.9330.92%39.19%
Jan 13, 2026New Street$6.00$4.4235.75%-35.76%
Dec 19, 2025Canaccord Genuity$25.00$17.2345.10%167.67%
Nov 13, 2024Benjamin BurnettStifel Nicolaus$10.00$7.5831.93%7.07%
Aug 16, 2024Salim SyedMizuho Securities$18.00$6.83163.54%92.72%
Aug 09, 2022Goldman Sachs$3.00$3.87-22.48%-67.88%
May 24, 2022Goldman Sachs$4.00$4.85-17.53%-57.17%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 20, 2024Rodman & RenshawBuyinitialise
Aug 09, 2022Goldman SachsSellSellhold
May 24, 2022Goldman SachsSellSellhold

Financial Forecast

EPS Forecast

$-150 $-110 $-70 $-30 $10 $50 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-90.78$-55.96$-65.18$-11.41$2.61---
Avg Forecast$-83.35$-50.03$-61.13$-9.50$-6.78$-6.34$-7.98$-5.86
High Forecast$-53.01$-35.93$-60.90$-2.03$-5.26$-0.84$1.42$-5.86
Low Forecast$-111.87$-69.65$-61.35$-15.99$-9.09$-15.02$-17.39$-5.86
Surprise %8.91%11.85%6.63%20.11%-138.50%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.34M$63.57M$8.57M$128.94M$120.77M---
Avg Forecast$41.63M$96.77M$6.77M$111.80M$79.75M$87.35M$148.29M$199.25M
High Forecast$52.58M$125.94M$7.38M$124.91M$79.75M$87.35M$148.29M$199.25M
Low Forecast$29.97M$75.78M$6.14M$98.70M$79.75M$87.35M$148.29M$199.25M
Surprise %-51.14%-34.30%26.65%15.33%51.44%---

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-340.14M$-228.30M$-276.13M$-85.40M$32.69M---
Avg Forecast$-307.71M$-233.47M$-276.13M$-38.18M$-30.40M$-33.59M$-33.83M$-24.83M
High Forecast$-246.16M$-172.19M$-204.44M$-8.60M$-22.29M$-3.55M$6.01M$-24.83M
Low Forecast$-369.25M$-294.75M$-347.82M$-67.76M$-38.51M$-63.64M$-73.66M$-24.83M
Surprise %10.54%-2.21%-123.71%-207.52%---

ATRA Forecast FAQ

Is Atara Biotherapeutics stock a buy?

Atara Biotherapeutics stock has a consensus rating of Hold, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 7 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Atara Biotherapeutics is a neutral investment for most analysts.

What is Atara Biotherapeutics's price target?

Atara Biotherapeutics's price target, set by 13 Wall Street analysts, averages $9.5 over the next 12 months. The price target range spans from $6 at the low end to $13 at the high end, suggesting a potential 1.71% change from the previous closing price of $9.34.

How does Atara Biotherapeutics stock forecast compare to its benchmarks?

Atara Biotherapeutics's stock forecast shows a 1.71% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Atara Biotherapeutics over the past three months?

  • May 2026: 0% Strong Buy, 33.33% Buy, 33.33% Hold, 33.33% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 33.33% Buy, 33.33% Hold, 33.33% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 25.00% Buy, 50.00% Hold, 25.00% Sell, 0% Strong Sell.

What is Atara Biotherapeutics’s EPS forecast?

Atara Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-6.34, marking a -342.91% decrease from the reported $2.61 in 2025. Estimates for the following years are $-7.98 in 2027, and $-5.86 in 2028.

What is Atara Biotherapeutics’s revenue forecast?

Atara Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $87.35M, reflecting a -27.67% decrease from the reported $120.77M in 2025. The forecast for 2027 is $148.29M, and $199.25M for 2028.

What is Atara Biotherapeutics’s net income forecast?

Atara Biotherapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-33.595M, representing a -202.77% decrease from the reported $32.69M in 2025. Projections indicate $-33.826M in 2027, and $-24.832M in 2028.